Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Resectable Sarcoma Clinical Trial

— TORNADO  

Official title:

Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04968106
• Other study ID #: IB 2021-01
• Secondary ID: 2021-001085-37
• Status: Recruiting
• Phase: Phase 2
• Start date: December 7, 2022
• Est. completion date: October 2027

Study information

• Verified date: March 2023
• Source: Institut Bergonié
• Contact: Antoine ITALIANO, MD, PhD
• Phone: +33556333333
• Email: a.italiano[@]bordeaux.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy

Description:

This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and retifanlimab) with one patient randomized in arm A for one patient randomized in arm B.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: October 2027
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with grade 2 or grade 3 soft-tissue sarcoma (limb, trunk wall, retroperitoneum) histologically confirmed and reviewed by the RRePS Network

2. For TLS status determination: available archived FFPE tumor tissue sample.

3. Presence of mature tertiary lymphoid structures. Except if presence of TLS have been already confirmed by Biopathological platform at Bergonié Institute, presence of TLS should be confirmed by central review based on FFPE tumor tissue sample (archived or newly obtained by biopsy for research purpose).

4. Non-metastatic and resectable disease,

5. At least one lesion that can be biopsied for research purpose,

6. No prior treatment for the disease under study,

7. Age = 18 years,

8. ECOG = 1,

9. Life expectancy > 3 months,

10. Patients must have measurable disease defined as per RECIST v1.1

11. Adequate hematological, renal, metabolic and hepatic function

12. Left ventricular ejection fraction = 50% assessed by ECHO or MUGA within 6 months from study entry,

13. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry. .

14. Both women and men must agree to use a highly effective method of contraception throughout the treatment period and for one year after discontinuation of treatment for women and 4 months for men.

15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, concomitant endometrial carcinoma stage IA grade 1, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,

16. Recovery to grade = 1 from any adverse event (AE) derived from previous treatment (excluding alopecia of any grade and non-painful peripheral neuropathy grade = 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 5),

17. Voluntarily signed and dated written informed consent prior to any study specific procedure,

18. Patients with a social security in compliance with the French law.

Exclusion Criteria:

1. Previous treatment for retroperitoneal sarcoma including surgery, chemotherapy or radiotherapy

2. Previous treatments with doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines or anthracenediones at the maximum cumulative dose,

3. Known hypersensitivity to any involved study drug or any of its formulation components,

4. Has an active or ongoing infection requiring systemic therapy,

5. Known central nervous system malignancy (CNS),

6. Women who are pregnant or breast feeding,

7. Has known active hepatitis B or hepatitis C,

8. Has a known history of Human Immunodeficiency Virus (HIV),

9. Previous enrolment in the present study,

10. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,

11. Has received a live attenuated vaccine or a live vaccine within 30 days prior to the first dose of trial treatment, Note: the killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.

12. Uncontrolled or significant cardiovascular disease including, but not limited to, any

of the following:

1. Myocardial infarction or stroke/transient ischemic attack within the 6 months prior to study entry.

2. Uncontrolled angina within the 3 months prior to study entry.

3. Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes, or poorly controlled atrial fibrillation).

4. Corrected QT (QTc) prolongation > 480 msec.

5. History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled venous thrombus).

13. Uncontrolled or significant renal disease including, but not limited to, any of the

following:

1. Acute or uncontrolled urinary infection at study entry,

2. Hemorrhagic cystitis at study entry,

3. Presence of blood on dipstick at study entry,

4. Vesical atony,

5. Known urinary tract obstruction.

14. Patients with known history of active inflammatory bowel diseases, including those with small or large intestine inflammation, such as Crohn's disease or ulcerative colitis, will be excluded from the study,

15. Has received systemic antibiotics within 14 days before the first dose of study treatment. Participants receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.

16. History of organ transplant, including allogeneic stem cell transplantation.

17. Receiving probiotics as of the first dose of study treatment.

18. Has an active autoimmune disease

• Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible,
• Patients requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at dose = 10 mg or 10 mg equivalent prednisone day,
• Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intra-ocular, intra-articular or inhalation) are acceptable.

19. Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis.

20. Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment. Note: Participants must have recovered from all radiation-related toxicities (to Grade >1 or baseline), not require corticosteroids for this purpose, and not have had radiation pneumonitis.

21. Person under judicial protection or deprived of liberty.

Related Conditions & MeSH terms

• Resectable Sarcoma
• Sarcoma

Intervention

Drug:
• Doxorubicin
Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
• Ifosfamide
Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
• INCMGA00012
Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles

Locations

Country	Name	City	State
France	Institut Bergonié	Bordeaux
France	Centre Léon Bérard	Lyon
France	Institut Curie	Paris
France	Institut Gustave Roussy	Villejuif

Sponsors (2)

Lead Sponsor	Collaborator
Institut Bergonié	Incyte Biosciences International Sàrl

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the antitumor activity of retifanlimab when prescribed in association with neoadjuvant chemotherapy (doxorubicin+ifosfamide)	Antitumor activity will be assessed in terms of histological response based on surgical sample	5 months after treatment onset
Secondary	1-year progression-free survival	Progression-free survival (PFS) is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)	1 year
Secondary	3-year progression-free survival	Progression-free survival (PFS) is defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause)	3 years
Secondary	1-year overall survival	Overall Survival (OS) is defined as the time from study treatment initiation to death (of any cause).	1 year
Secondary	3-year overall survival	Overall Survival (OS) is defined as the time from study treatment initiation to death (of any cause).	3 years
Secondary	Safety profile independently for each arm: Common Terminology Criteria for Adverse event version 5	Toxicity will be grade using the Common Terminology Criteria for adverse events version 5 and coded according to the standardized medical terminology MedDRA	Throughout the treatment period, an expected average of 6 months